title: Notes from the field: Multistate outbreak of postprocedural fungal endophthalmitis associated with a single compounding pharmacy - United States, March-April 2012.
abstract: On March 5, 2012, the California Department of Public Health was notified of nine cases of clinically diagnosed fungal endophthalmitis at a single California ambulatory surgical center. The initial investigation, led by the Los Angeles County Department of Public Health, determined that in all cases patients had undergone vitrectomy with epiretinal membrane peeling using a dye called Brilliant Blue-G (BBG) from Franck's Compounding Lab, Ocala, Florida. This investigation has since expanded to involve intravitreal injection of triamcinolone-containing products from Franck's, an overall total of 33 cases in seven states, and collaboration between state and local health departments, CDC, and the Food and Drug Administration (FDA). This report describes the current investigative findings. Clinicians should be aware of the ongoing investigation and should avoid use of compounded products labeled as sterile from Franck's during this ongoing investigation.
mesh_terms: D001203:Ascomycota / Q000302:isolation & purification; D004196:Disease Outbreaks; D004339:Drug Compounding; D004340:Drug Contamination; D004348:Drug Labeling; D009877:Endophthalmitis / Q000453:epidemiology* / Q000209:etiology; D060585:Fusariosis / Q000453:epidemiology* / Q000209:etiology; D005670:Fusarium / Q000302:isolation & purification; D006801:Humans; D007202:Indicators and Reagents / Q000009:adverse effects* / Q000737:chemistry; D013508:Ophthalmologic Surgical Procedures / Q000009:adverse effects*; D010594:Pharmacies; D012394:Rosaniline Dyes / Q000009:adverse effects* / Q000737:chemistry; D014481:United States / Q000453:epidemiology; D014821:Vitrectomy / Q000009:adverse effects
chemical_list: D007202:Indicators and Reagents; D012394:Rosaniline Dyes; C004692:coomassie Brilliant Blue